Blog

In the biopharma industry, understanding how your therapy basket’s fill rate stacks up against competitors can be a game-changer. This blog post dives deep into the significance of therapy basket fill rates, providing exclusive data insights and practical tips to help biopharma executives stay ahead in the competitive landscape. The Importance of Therapy Basket Fill […]

Picture a future in which we don’t merely manage symptoms but eliminate diseases at their roots. This future isn’t a far-off dream; it’s the promise of cell therapy. This innovative approach is currently changing the way we confront some of the toughest medical conditions. For biopharma investors, this arena doesn’t only symbolize a leap in

Mantle cell lymphoma (MCL) is a rare yet aggressive form of non-Hodgkin lymphoma, and treatment options have been limited for far too long. For pharmaceutical professionals and biopharma executives, staying at the forefront of treatment innovations is crucial. Recently, AstraZeneca has made significant strides with its BTK inhibitor, Calquence, challenging the current standard of care

The FDA unveiled a much-anticipated draft guide, outlining how businesses can secure approvals for platform technologies. This regulatory advance has the potential to fast-track the FDA’s ‘platform technology’ procedure, potentially accelerating the endorsement of cell and gene therapies. Keen to find out more? This comprehensive 15-page draft guide provides a wealth of knowledge for biopharma

AstraZeneca is experiencing tremendous success and progress under the leadership of CEO Pascal Soriot. His current objective is to achieve a revenue target of $80 billion by 2030. A decade ago, when AstraZeneca was experiencing a period of stagnation, the CEO projected a bold revenue goal of $45 billion by 2023. In a triumphant turn

The U.S. Food and Drug Administration (FDA) has given the green light to Amgen’s monoclonal antibody Bkemv, the first interchangeable biosimilar for Alexion’s top-selling drug Soliris. This provides a pathway for more affordable treatments for rare blood diseases. Let’s take a closer look at what this means for the industry, medical practitioners, and patients. Deciphering

Tuesday brought good news for asthma sufferers and the healthcare community alike, courtesy of GSK. The pharmaceutical firm announced the successful reduction of annual asthma attacks in two pivotal clinical trials of its experimental antibody treatment named Depemokimab. The trials involved adults and adolescents afflicted with a form of severe asthma. GSK’s newly developed long-lasting

In an exciting development for the biopharma industry, Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This strategic alliance is a testament to the increasingly intertwined future of the technology and pharmaceutical sectors. This announcement follows closely on the heels of OpenAI’s other significant alliance with

Walgreens, a powerhouse in the retail and wholesale pharmaceutical sector, embarked on an unprecedented path with an impressive service upgrade – the incorporation of gene and cell therapies. This strategy extends Walgreens’ existing service portfolio and significantly advances healthcare. Let’s explore this groundbreaking endeavor and what it means for customers. Walgreens is expanding its specialty

The Food and Drug Administration (FDA) has recently been the center of attention in the biopharmaceutical world, pushing for a notable shift in the discourse surrounding biosimilars. The federal agency has openly campaigned for the abolition of ‘interchangeability‘ – a term it perceives as causing more confusion than clarity and adversely impacting the market penetration